Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Octreotide for pulmonary contusion
IRCT20201013049017N5Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Oct 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Lung Contusion comparing Octreotide plus routine care with Placebo saline plus routine care (2 arms). Primary endpoints: Inflammatory factors, Coagulation factors and 2 more. Started Oct 2025; status: completed.
02
Drugs
octreotide
03
Conditions
Lung Contusion
Beyond the preview
Go deeper on IRCT20201013049017N5.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20201013049017N5.